Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of December 2017, with the report signed on December 22, 2017. The filing serves as a Change of Director's Interest Notice under ASX Listing Rule 3.19A.2 and Section 205G of the Corporations Act. The registrant is a foreign private issuer based in Parkville, Victoria, Australia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is a transaction involving Dr. George Mihaly, a Director of the company, on December 19, 2017:
- Options Acquired: Dr. Mihaly acquired 1,250,000 unlisted options under the Employee Share Option Plan.
- Options Lapsed: 1,000,000 previously held options lapsed.
- Net Position: Following the transaction, Dr. Mihaly holds a total of 1,250,000 options and 226,666 shares (comprising 166,666 direct and 60,000 indirect holdings).
- Consideration: The filing references an Explanatory Memorandum from the 2017 Annual General Meeting for details on consideration but does not state a specific monetary value in this text.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, or specific risk factors. The document confirms that the transaction did not occur during a closed period requiring prior written clearance.
Investor Verification Checklist
- Verify the terms and vesting schedule of the 1,250,000 new options granted to Dr. Mihaly by reviewing the 2017 Notice of Annual General Meeting Explanatory Memorandum.
- Confirm the total outstanding option pool and the impact of the lapse of 1,000,000 options on the company's capital structure.
- Review the company's latest financial reports (Form 20-F) for actual revenue, cash flow, and liquidity data, as this 6-K filing contains none.